SI3921030T1 - Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq - Google Patents
Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnqInfo
- Publication number
- SI3921030T1 SI3921030T1 SI202030316T SI202030316T SI3921030T1 SI 3921030 T1 SI3921030 T1 SI 3921030T1 SI 202030316 T SI202030316 T SI 202030316T SI 202030316 T SI202030316 T SI 202030316T SI 3921030 T1 SI3921030 T1 SI 3921030T1
- Authority
- SI
- Slovenia
- Prior art keywords
- kcnq
- potentiators
- trifluoroethoxy
- pyridin
- methyl
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| EP20709409.5A EP3921030B1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3921030T1 true SI3921030T1 (sl) | 2024-03-29 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202030316T SI3921030T1 (sl) | 2019-02-06 | 2020-02-04 | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11208383B2 (sl) |
| EP (1) | EP3921030B1 (sl) |
| JP (2) | JP7451543B2 (sl) |
| KR (1) | KR20210126040A (sl) |
| CN (1) | CN113692304A (sl) |
| AU (1) | AU2020218180A1 (sl) |
| BR (1) | BR112021015544A2 (sl) |
| CA (1) | CA3128975A1 (sl) |
| DK (1) | DK3921030T3 (sl) |
| ES (1) | ES2968807T3 (sl) |
| FI (1) | FI3921030T3 (sl) |
| HR (1) | HRP20240012T1 (sl) |
| HU (1) | HUE064734T2 (sl) |
| IL (1) | IL285113A (sl) |
| LT (1) | LT3921030T (sl) |
| MX (1) | MX2021009396A (sl) |
| PL (1) | PL3921030T3 (sl) |
| PT (1) | PT3921030T (sl) |
| RS (1) | RS65040B1 (sl) |
| SA (1) | SA521422733B1 (sl) |
| SG (1) | SG11202108599SA (sl) |
| SI (1) | SI3921030T1 (sl) |
| SM (1) | SMT202400003T1 (sl) |
| WO (1) | WO2020163268A1 (sl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3921030T1 (sl) * | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq |
| JP2023531500A (ja) | 2020-06-25 | 2023-07-24 | イドーシア ファーマシューティカルズ リミテッド | シクロブチル－ウレア誘導体 |
| TW202330471A (zh) * | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 環丙醯胺衍生物 |
| EP4433453A1 (en) | 2021-11-19 | 2024-09-25 | Icagen, LLC | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| WO2023091461A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Pyridine compounds as kv7.2 enhancers |
| CN118510757A (zh) | 2021-12-22 | 2024-08-16 | 伊卡根有限责任公司 | 环丙基化合物 |
| WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
| IT202200024963A1 (it) | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK130599A3 (en) * | 1997-03-25 | 2000-05-16 | Astra Pharma Prod | Novel pyridine derivatives and pharmaceutical compositions containing them |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| CA2560346A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| CA2575003C (en) * | 2004-07-29 | 2010-02-16 | Merck & Co., Inc. | Potassium channel inhibitors |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| WO2012116440A1 (en) * | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| RU2769607C2 (ru) | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность |
| US9676757B2 (en) * | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| RU2712163C2 (ru) * | 2014-10-24 | 2020-01-24 | Оно Фармасьютикал Ко., Лтд. | Активатор kcnq2-5 каналов |
| ES2866324T3 (es) | 2016-04-22 | 2021-10-19 | Ono Pharmaceutical Co | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria |
| SI3921030T1 (sl) * | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq |
-
2020
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 SM SM20240003T patent/SMT202400003T1/it unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 CN CN202080012797.0A patent/CN113692304A/zh active Pending
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko not_active Application Discontinuation
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
-
2021
- 2021-07-25 IL IL285113A patent/IL285113A/en unknown
- 2021-08-05 SA SA521422733A patent/SA521422733B1/ar unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US20240076269A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE064734T2 (hu) | 2024-04-28 |
| SG11202108599SA (en) | 2021-09-29 |
| HRP20240012T1 (hr) | 2024-03-29 |
| SA521422733B1 (ar) | 2024-02-08 |
| CN113692304A (zh) | 2021-11-23 |
| US20200247752A1 (en) | 2020-08-06 |
| US11840516B2 (en) | 2023-12-12 |
| IL285113A (en) | 2021-09-30 |
| US20220073464A1 (en) | 2022-03-10 |
| KR20210126040A (ko) | 2021-10-19 |
| BR112021015544A2 (pt) | 2021-10-26 |
| JP7451543B2 (ja) | 2024-03-18 |
| ES2968807T3 (es) | 2024-05-14 |
| CA3128975A1 (en) | 2020-08-13 |
| DK3921030T3 (da) | 2024-01-02 |
| JP2024063191A (ja) | 2024-05-10 |
| SMT202400003T1 (it) | 2024-03-13 |
| PT3921030T (pt) | 2024-01-12 |
| LT3921030T (lt) | 2024-01-25 |
| MX2021009396A (es) | 2021-09-10 |
| PL3921030T3 (pl) | 2024-05-06 |
| US20240076269A1 (en) | 2024-03-07 |
| JP2022519744A (ja) | 2022-03-24 |
| AU2020218180A1 (en) | 2021-08-19 |
| FI3921030T3 (fi) | 2024-01-08 |
| EP3921030B1 (en) | 2023-10-11 |
| RS65040B1 (sr) | 2024-02-29 |
| US11208383B2 (en) | 2021-12-28 |
| EP3921030A1 (en) | 2021-12-15 |
| WO2020163268A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285113A (en) | History of 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea as kcnq enhancers | |
| DK3833670T3 (da) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorphenyl)-2-methylpyrimidin-4(3h)-on-derivater og lignende forbindelser som PTPN11- (SHP2) hæmmere til cancerbehandling | |
| EP4077311A4 (en) | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES | |
| RS66162B1 (sr) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-l-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-l-il)-3-fluorobenzonitril kao antiproliferativno jedinjenje | |
| SG11202106706TA (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| MX2017009892A (es) | Agente terapeutico contra el colangiocarcinoma. | |
| EP1954683A4 (en) | 2- (PHENYL OR HETEROCYCLIC) -1H-PHENANTRHO (9,10-D) IMIDAZOLES AS INHIBITORS OF MPGES-1 | |
| IL268690A (en) | (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them | |
| LT3985000T (lt) | 2,4-dipakeistasis pirimidino darinys, jo gamybos būdas ir panaudojimas | |
| IL282006B1 (en) | Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| EP3553057A4 (en) | (HETERO) ARYLAMIDE COMPOUND TO INHIBIT PROTEIN KINASE ACTIVITY | |
| IL285675A (en) | Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| SI3559010T1 (sl) | Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega | |
| IL255224B (en) | Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | |
| MX2018006329A (es) | Agente terapeutico para cancer de mama. | |
| DK3947711T3 (da) | Urinstofbiosensorer, der er stabiliseret ved rumtemperatur | |
| EP3541796A4 (en) | 4 - ((6- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| MX2023001805A (es) | Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. | |
| IL289953A (en) | History of 4-(imidazo[a-2,1]pyridine-3-yl)-pyrimidine and its use in cancer | |
| EP3541801A4 (en) | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| DK2240456T3 (da) | Fremgangsmåde til fremstilling af 3, 5-dihydro-L, 3, 5-triazinderivater af metformin- og paraldehydderivater | |
| IL288577A (en) | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide | |
| EP4069228A4 (en) | PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE | |
| MX2019000749A (es) | Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il) -6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-i midazol-2-carboxamida. |